Relationship between mitotic index and Ki67 expression in meningioma

Rini Yusriany, Muhammad Husni Cangara, Cahyono Kaelan, Gunawan Asyadi, Ni Ketut Sungowati, Andi Ihwan, Rohadi Muhammad Rosyidi, Andi Alfian Zainuddin


Background: Meningioma is the most common primary central nervous system (CNS) tumor which covers 36.4% of all CNS tumors. Two important factors determining the prognosis of patients with a diagnosis of meningioma are the percentage of tumor resection and the degree of tumor histopathology. Because there are limitations to routine histopathological examination in predicting tumor progressivity, several examination techniques have been developed including cytogenetics and use of immunohistochemical examination.

Method: Observational analytic study was carried out on 68 tumor samples in dr. Wahidin Sudirohusodo Hospital and the Makassar Pathology Diagnostic Center with diagnoses of meningioma from 2012-2018. The Sample size is determined by consecutive sampling method.

Results: Sample Size were 68 people from Dr. Wahidin Sudirohusodo Hospital and the Makassar Pathology Diagnostic Center with diagnoses of meningioma which fulfilled the inclusion criteria and consisted of 19(27.9%) men and 49 (72.1%) women with an average age of 42 years. The most common location of the tumor was in the convexity area with an incidence of 29.4%. Grade I meningioma was found 41.2%, grade II of 32.4% and grade III of 26.5%. In grade I, the mean mitotic index was 0.25, grade II was (7.4) and grade III was 22.75. In grade I, the mean Ki67 expression was 1.01%. The highest expression was obtained in grade III with amean of 14.8% and the highest expression was 53%. The Spearman’s rho test results between the mitotic index and Ki67 expression show that there is a positive correlation of 0.490, which means that there is a moderate correlation.

Conclusion: IHC expression of Ki67 increases proportionally to the degree of histopathology of meningioma. There is a positive correlation of 0.490 which means that there is a moderate correlation between the mitotic index and Ki67 expression.


Immunohistochemical examinations, Ki67 expression, Meningioma, The mitotic index

Full Text:



CDTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002-2006. Central Brain Tumor Registry of the United States, Hisdale. 2009-2010

Li X, Zhao J. Intracranial meningiomas of childhood and adolescence: report of 34 cases with follow-up. Child's Nerv Sys. 2009 Nov 1;25(11):1411.

Samadi N, Ahmadi SA. Meningioma: A Clinicopathological Evaluation. Malays J Med Sci. 2007 Jan;14(1):46-52.

Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW. Relationship between tumor location, size, and WHO grade in meningioma. Neurosurgical focus. 2018 Apr 1;44(4):E4.

Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J clin exp pathol. 2012;5(3):231-42.

Commins, DL, Atkinson RD, Burnett ME. Review of Meningioma Histopathology, Neurosurg Focus, 2007;23(4);1-9.

Takahashi JA, Ueba T, Hashimoto N, Nakashima Y, Katsuki N. The Combination of Mitotic and Ki-67 Indices as a Useful Method for Predicting Short-Term Recurrence of Meningiomas. Surg Neurol. 2004;61(2):149-56.

Abry E, Thomassen IØ, Salvesen ØO, Torp SH. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study. Pathology-Research and Practice. 2010 Dec 15;206(12):810-5.

Ramesh BT, Amit KC, Nandya LR, Rashmi Patnayak, Bobbi DP, et al. Histopathological and Immunohistochemical Evaluation of Meningiomas with Reference to Proliferative Markers p53 and Ki-67, J Clin Diagnostic Research. 2016;10(1);5-19.

Kolles H, Niedermayer C. Schmitt W. Henn R. Feld WI, Steudel, Triple approach for diagnosis and grading of meningiomas: Histology, morphometry of Ki-67/feulgen stainings, and cytogenetics. Acta Neurochirurgica, 1995;137(3-4):174-81.

Striepecke E, Handt S, Weis J, Koch A, Cremerius U, Reineke T, et al. Correlation of Histology, Cytogenetics and Proliferation, Fraction (Ki-67 and PCNA) Quantitated by Image Analysis in Meningiomas. Pathology-Research and Practice. 1996 Jan 1;192(8):816-24.

Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, et al. Pathodiagnostic parameters for meningioma grading. J Clin Neurosc. 2008 Dec 1;15(12):1370-5.

Üzüm N, Ataoğlu GA. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori J. 2008 May;94(3):389-97.

Caly M, Genin P, Al Ghuzlan A, Elie C, Freneaux P, Klijanienko J, et al. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer research. 2004 Sep 1;24(5B):3283-8.

Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am J surg pathol. 2001 Apr 1;25(4):472-8.

Vankalakunti M, Vasishta RK, Radotra BD, Khosla VK. MIB‐1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathol. 2007 Oct;27(5):407-12.

Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta neurochirurgica. 2004 Jan 1;146(1):37-44.

Bruna J, Brell M, Ferrer I, Gimenez‐Bonafe P, Tortosa A. Ki‐67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathol. 2007 Apr;27(2):114-20.

Nakano T, Oka K. Differential values of ki‐67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer. 1993 Oct 15;72(8):2401-8.